| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| OR-2805 | OR-2805 | Phase 2 Clinical | OncoResponse Inc | Solid tumours; Leiomyosarcoma; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Liposarcoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Melanoma | Details |
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Tetrachlorodecaoxide | TCDO; WF-10; OXO-K993 | Approved | Nuvox Pharma LLC | WF10, Oxoferin, Immunokine | Thailand | Rhinitis, Allergic; Inflammation | null | 1997-01-01 | Diabetic Foot; HIV Infections; Rhinitis, Allergic; Inflammation | Details |

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland



